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Use of adsorptive mechanisms in continuous renal replacement catabolism and hyperhydration. In addition to removing
therapies in the critically ill. The pathophysiology of sepsis is excess fluid and sodium in septic patients, the removal
becoming a more complicated scenario. In sepsis, endotoxin of LPS and other mediators by CRRTs has introducedor other gram-positive derived products induce a complex and
the new concept of blood purification [6–15]. In experi-dynamic cellular response giving rise to several mediators
mental studies, blood filtration may remove several me-known to be relevant in the pathogenesis of septic shock, such
as specific mediators, substances responsible for up- or down- diators simultaneously. However, removal rates and
regulation of cytokine receptors and cytokine antagonists, inac- clearances of the different proinflammatory cytokines
tivators of nuclear factor-kB or signal transduction pathways,
such as interleukin-1 (IL-1), tumor necrosis factorand precursor molecules. In this article, we delve into some
(TNF), and platelet-activating factor (PAF) are hinderednew concepts stemming from the use of sorbents in continuous
plasma filtration. The rationale is based on the assumption that by poor membrane passage [9–17]. For this reason, the
the nonspecific removal of several mediators of the inflamma- fulfillment and even the very rationale of blood purifica-
tory cascade and cytokine network may improve outcome in tion in CRRT have been disputed. The concept of aa rabbit model of septic shock and hemodynamics in a pilot
continuous therapy in critically ill patients is self-evident.clinical study. The importance of looking for innovative treat-
These are patients who, aside from their quite unstablements specifically targeted for the special needs of the critically
ill patients rather than using concepts and technology applied hemodynamics, are in need of a high calorie intake and
to the treatment of chronic renal failure is underlined. an intravenous drug administration that must be in bal-
ance with poorly functioning kidneys.
Sepsis develops as a result of the host response to infec-
HIGH CONVECTION VERSUS INCREASEDtion [1]. Bacterial components such as the lipid A-con-
SIEVING COEFFICIENTS: TWO POSSIBLEtaining lipopolysaccharide (LPS) in the cell wall of gram-
ALLEYS FOR INNOVATION IN CRRTnegative bacteria trigger a global response that involves
both cellular and humoral systems with the generation of Conventional CRRTs have gained increased popular-
both proinflammatory and anti-inflammatory activities ity for their ability to ensure the removal of excess fluid
[2–4]. and sodium in septic patients. In order to enhance the
Although several attempts have targeted specific com- removal of septic-associated mediators, two approaches
ponents in the proinflammatory septic cascade, no im- have been taken under consideration. In their original
provement in survival has been obtained in large-scale proposal, Grootendorst et al suggested that high-volume
clinical trials [reviewed in 5]. (100 liter/day) hemodiafiltration could remove cardiac
Continuous renal replacement therapies (CRRT) also depressant activity and other sepsis mediators in the
have made extracorporeal treatment possible in hemo- ultrafiltrate in a pig model of septic shock [18]. In a
dynamically unstable patients in order to balance hyper- subsequent clinical study, Bellomo et al further impli-
cated this possibility, as evidenced by a significant reduc-
tion in norepinephrine administration [19]. The otherKey words: sepsis, cytokines, inflammation, acute renal failure, hemo-
dynamics. approach has been to use larger pore membranes than
those currently used in hemofiltration. Lee et al sug- 1999 by the International Society of Nephrology
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Fig. 1. Criteria to assess the efficiency of plasma filtration versus ultrafiltration to study in vitro the adsorption of sepsis-associated mediators
tumor necrosis factor-a (TNF-a), interlukin-1b (IL-1b), IL-8, and platelet activating factor (PAF). Symbols are: ( ) % removed mass; ( ) %
drop in concentration; (j) clearance.
gested an increased survival in a porcine model of septic Treatment modalities have been either hemoperfusion,
double-chamber hemodiafiltration, or plasma separationshock and related it to an enhanced overall blood purifi-
cation [20]. Other authors have reported the benefits in with sorbent adsorption. Although hemoperfusion has
the advantage of a much simpler circuit, it may requiresurvival when using plasmapheresis in both animal [21]
and human [22] studies. In vitro studies showed that the sorbents to be rendered biocompatible for the direct
contact with blood and with blood cells particularly. Inplasma filtration allowed the removal of higher amounts
of proinflammatory cytokines (such as TNF-a, IL-1b, the case of charcoals, which exhibit a high adsorbent
capacity, especially for low molecular weight waste prod-IL-8). Clearances and sieving coefficients of these cyto-
kines were greatly and significantly increased with “open” ucts that accumulate during kidney or liver failure, their
use in hemoperfusion requires them to be used in “coated”plasma filtration membranes rather than with high per-
forms. However, coated charcoals, albeit biocompatible,meability membranes (Fig. 1) [23].
have a remarkably reduced adsorptive capacity. The alter-However, plasmapheresis is hardly as considerable or
native has been the use of sorbents in an “uncoated” formeffective as a CRRT. The combination of the two re-
on the ultrafiltrate or the plasma filtrate [reviewed inquirements, that is, higher sieving coefficient and contin-
24]. In the field of hemoperfusion, besides the widely-uous therapy, has led to the implication of sorbents in
used coated charcoal (Detoxyl, Sorin), new applicationsaffecting the experimental or clinical outcome.
such as heparin removal devices (HRD)s, using plasma
separation and poly-l-lysine affinity adsorption have
SORBENTS IN EXTRACORPOREAL THERAPIES been shown to be an effective alternative to protamine
The use of sorbents in extracorporeal therapies is not after cardiopulmonary bypass [25]. Different commer-
new. Classically, hemoperfusion and more recently aph- cially available sorbents for specific target molecules in
eresis have witnessed intensive research in this area. human disease, when they are considered of pathoge-
Sorbents may be of a natural origin, such as charcoal netic relevance, such as low-density lipoproteins [DALI
(mineral or vegetable) or synthetic (different resins with (Fresenius, Bad Homburg, Germany), Liposorber (LA-
15; Kaneka), LDL-Therasorb (Baxter, McGaw Park, IL,covalently bound groups reactive with specific ligands).
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Fig. 2. Plasma treatment in sepsis including
the criteria to assess the efficiency of the sor-
bent.
USA)], immune complexes, antibodies, or activated adsorption resulted in a significant survival (P 5 0.0041;
complement components [Therasorb (Baxter), Prosor- 85%) at 72 hours with respect to rabbits injected with
bat or MIRO (Fresenius)], or anti-DNA antibodies (Im- LPS, but not treated with coupled plasma-filtration ad-
munosorba PH-350 and TR-350; Asahi Medical Co., sorption. In the pathogenesis of gram-negative infec-
Ltd., Tokyo, Japan; Selesorb, Kaneka Co., Osaka, Ja- tions, the complex and dynamic host interaction involves
pan). In apheresis, there has been a widespread tendency the inflammatory cascade, complement activation, coag-
to remove “bad factors” rather than to attempt to bring ulation, and hemodynamic and physiological parameters
about a restoration of balance of physiological factors. [26–28]. In fact, improved survival was negatively corre-
Often, too much emphasis is on individual markers, and lated with the severity score that included plasma LPS,
treatments need to focus on a “balancing hypothesis” bioactive TNF as well as mean arterial protein (MAP),
such as immunological suppression versus activation. base excess (BE), and white blood cells (WBC). How-
This becomes particularly true when the converging con- ever, cumulative survival was not correlated with the
cepts of plasma filtration coupled with sorbent adsorp- levels of circulating TNF. It must be emphasized that
tion are to be applied to the very complex scenario of the overall net effect on survival could be due to the
severe sepsis evolving in septic shock. removal not only of the mediators that we measured, but
also to many other mediators not monitored in our study.
Finally, we cannot rule out that the simultaneous removalUSE OF SORBENTS IN THE TREATMENT OF
of different mediators could possibly prevent the forma-CRITICALLY ILL PATIENTS
tion of other biologically active substances such as pros-The rationale for sorbent adsorption in a plasma fil-
taglandins/leukotrienes, other cytokines, molecules thattration system is to reinfuse endogenous plasma after
up- or down-regulate membrane receptors, selectins, andnonselective simultaneous removal of different sepsis-
adhesion molecules. Many new therapeutic strategiesassociated mediators without the need of donor plasma.
have targeted single molecules but thus far have failedThis rationale was based on a series of studies in vitro,
to lower the mortality rates [reviewed in 5]. Whetheranimal and a preliminary, ethical committee-approved
the simultaneous removal of different mediators wasclinical trial according to the European legislation for
linked in a cause–effect relationship with improved sur-unregistered biomedical devices (EN 540; Fig. 2). In vitro
vival in our experimental model was strongly suggested,studies demonstrated that removal rates were different
and may provide the rationale for blood purification toaccording to varying sorbents tested [23]. More impor-
CRRT [reviewed in 29].tantly, when tested at different linear velocities, their
A clinical trial, which was a prospective, randomizedefficiencies in removing cytokines, albeit reduced, were
cross-over trial aimed at comparing the clinical and bio-far away above the mass of individual cytokines calcu-
logical effects of coupled plasma-filtration adsorptionlated on the basis of the highest levels detected in the
(CPFA; Fig. 3) versus continuous venovenous hemofil-plasma of septic patients [23]. Animal studies were per-
tration (CVVH) in critically ill septic patients, has re-formed in a model of septic shock in the rabbit (abstract;
cently been concluded, and preliminary data were pre-Tetta et al, J Am Soc Nephrol 9:A3008, 1998). The
sented in abstract form (abstract; Brendolan et al, J Ammodel consisted on a single intravenous injection of LPS
Soc Nephrol 9:A0655, 1998) (Fig. 4). The major findingsat a dose that was experimentally assessed to determine
a mortality of 80% at 72 hours. Coupled plasma-filtration can be summarized as follows. Despite the fact that all
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Fig. 3. Development of plasma filtration cou-
pled with sorbent adsorption (CPFA).
Fig. 4. Criteria used to assess the efficiency
of innovative techniques to treat sepsis.
patients had relatively low plasma concentrations of cy- should verify the clinical significance of restoring mono-
tokines (TNF-a, IL-1b), the sorbent adsorbed almost cyte responsiveness. Beside CPFA, other systems are
100% of the cytokines in the plasma filtrate. In all pa- now in the process of being evaluated in clinical trials.
tients starting the treatment, the in vitro TNF production The detoxification plasma filtration (DTPF) system
of circulating monocytes to exogenous LPS was remark- (HemoCleanse, Inc., West Lafayette, IN, USA) com-
ably impaired compared to the monocytes from healthy bines the DT hemodiabsorption system in series with a
subjects. When the same patient was studied after five push-pull pheresis plasma-filtration system (a suspension
hours of treatment with CPFA, the ability of monocytes of powdered sorbents surrounding 0.5 micron plasma
to produce TNF-a was restored in the range seen for filter membranes). Bidirectional plasma flow (at 80 to 100
normal monocytes. Coincubation experiments with a ml/min) across the plasma filtration membranes provides
monoclonal antibody directed against IL-10 could abro- direct contact between plasma proteins and powdered
gate (60%) the monocyte unresponsiveness. In CVVH, sorbents, as well as clearance of cytokines (TNF-a, IL-1b,
abrogation of monocyte unresponsivess was only partial and IL-6) at a rate of 15 to 25 ml/min, without evidence
as compared with CPFA, and was significantly delayed
of saturation for 90 minutes. In a U.S. Food and Drug
(after 10 hr of treatment). At the hemodynamic level,
Administration-approved study, eight patients with sys-all patients (APACHE score .20) showed increased
temic inflammatory response syndrome (SIRS) and or-peripheral vascular resistances that allowed a significant
gan failure underwent a single DTPF treatment, usingreduction in the dose of vasopressor drugs at five hours
powdered charcoal as sorbent in four patients and pow-and remained steadily low after 10 hours of treatment.
dered charcoal and silica in four patients [30]. TreatmentThe reduction of vasopressor drugs was not observed
proceeded for six hours. All patients improved duringduring CVVH. These data suggest the possibility that
the treatment, and each had increased blood pressureCPFA may ensure better hemodynamics in highly unsta-
and decreased need for pressor agents. Plasma cytokineble patients than CVVH. Because the CPFA may be
levels stabilized or decreased during treatment and weremodular to conventional CVVH, the system may ensure
significantly lower the morning after treatment. Multiplea fluid and salt balance together with an enhanced blood
organ dysfunction (MOD) and Acute Physiology Chronicpurification. A prospective, randomized clinical trial in-
volving a large cohort of patients is anticipated and Health Evaluation II scores and organ function gradually
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